Page 1323 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 71 Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes 1169

REFERENCES 16. Burgstaller S1, Kreil S, Waghorn K, et al: The severity of FIP1L1-
PDGFRA-positive chronic eosinophilic leukaemia is associated with
1. Kita H: Eosinophils: multifaceted biological properties and roles in polymorphic variation at the IL5RA locus. Leukemia 21:2428, 2007.
health and disease. Immunol Rev 242:161, 2011. 17. Valent P, Gleich GJ, Reiter A, et al: Pathogenesis and classification of
2. Yousefi S, Simon D, Simon HU: Eosinophil extracellular DNA traps: eosinophil disorders: a review of recent developments in the field. Expert
molecular mechanisms and potential roles in disease. Curr Opin Immunol Rev Hematol 5:157, 2012.
24:736, 2012. 18. Plötz SG, Hüttig B, Aigner B, et al: Clinical overview of cutaneous
3. Valent P, Klion AD, Horny HP, et al: Contemporary consensus proposal features in hypereosinophilic syndrome. Curr Allergy Asthma Rep 12:85,
on criteria and classification of eosinophilic disorders and related syn- 2012.
dromes. J Allergy Clin Immunol 130:607, 2012. 19. Gotlib J, Akin C: Mast cells and eosinophils in mastocytosis, chronic
4. Bochner BS, Schleimer RP: Mast cells, basophils, and eosinophils: eosinophilic leukemia, and non-clonal disorders. Semin Hematol 49:128,
distinct but overlapping pathways for recruitment. Immunol Rev 179:5, 2012.
2001. 20. Valent P, Horny HP, Bochner BS, et al: Controversies and open questions
5. Valent P: The phenotype of human eosinophils, basophils, and mast in the definitions and classification of the hypereosinophilic syndromes
cells. J Allergy Clin Immunol 94:1177, 1994. and eosinophilic leukemias. Semin Hematol 49:171, 2012.
6. Bochner BS: Siglec-8 on human eosinophils and mast cells, and Siglec-F 21. Wimazal F, Germing U, Kundi M, et al: Evaluation of the prognostic
on murine eosinophils, are functionally related inhibitory receptors. Clin significance of eosinophilia and basophilia in a larger cohort of patients
Exp Allergy 39:317, 2009. with myelodysplastic syndromes. Cancer 116:2372, 2010.
7. Tai PC, Ackerman SJ, Spry CJ, et al: Deposits of eosinophil granule 22. Gleich GJ, Schroeter AL, Marcoux JP, et al: Episodic angioedema associ-
proteins in cardiac tissues of patients with eosinophilic endomyocardial ated with eosinophilia. N Engl J Med 310:1621, 1984.
disease. Lancet 1:643, 1987. 23. Vaglio A, Moosig F, Zwerina J: Churg-Strauss syndrome: update on
8. Gauvreau GM, Ellis AK, Denburg JA: Haemopoietic processes in allergic pathophysiology and treatment. Curr Opin Rheumatol 24:24, 2012.
disease: eosinophil/basophil development. Clin Exp Allergy 39:1297, 24. Schwartz LB, Sheikh J, Singh A: Current strategies in the management
2009. of hypereosinophilic syndrome, including mepolizumab. Curr Med Res
9. Lampinen M, Carlson M, Håkansson LD, et al: Cytokine-regulated Opin 26:1933, 2010.
accumulation of eosinophils in inflammatory disease. Allergy 59:793, 25. Rothenberg ME, Klion AD, Roufosse FE, et al: Treatment of patients
2004. with the hypereosinophilic syndrome with mepolizumab. N Engl J Med
10. Sadovnik I, Lierman E, Peter B, et al: Identification of Ponatinib as 358:1215, 2008.
a potent inhibitor of growth, migration, and activation of neoplastic 26. Jovanovic JV, Score J, Waghorn K, et al: Low-dose imatinib mesylate
eosinophils carrying FIP1L1-PDGFRA. Exp Hematol 42:282, 2014. leads to rapid induction of major molecular responses and achievement
11. Hoermann G, Cerny-Reiterer S, Sadovnik I, et al: Oncostatin M is of complete molecular remission in FIP1L1-PDGFRA-positive chronic
a FIP1L1/PDGFRA-dependent mediator of cytokine production in eosinophilic leukemia. Blood 109:4635, 2007.
chronic eosinophilic leukemia. Allergy 68:713, 2013. 27. Apperley JF, Gardembas M, Melo J, et al: Response to imatinib mesylate
12. Kiwamoto T, Kawasaki N, Paulson JC, et al: Siglec-8 as a drugable target in patients with chronic myeloproliferative diseases with rearrangements
to treat eosinophil and mast cell-associated conditions. Pharmacol Ther of the platelet-derived growth factor receptor beta. N Engl J Med 347:481,
135:327, 2012. 2002.
13. Cross NC, Reiter A: Fibroblast growth factor receptor and platelet-derived 28. Klion AD, Robyn J, Maric I, et al: Relapse following discontinuation
growth factor receptor abnormalities in eosinophilic myeloproliferative of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic
disorders. Acta Haematol 119:199, 2008. eosinophilic leukemia: implications for optimal dosing. Blood 110:3552,
14. Gotlib J: World Health Organization-defined eosinophilic disorders: 2007.
2015 update on diagnosis, risk stratification, and management. Am J 29. Radonjic-Hoesli S, Valent P, Klion AD, et al: Novel targeted therapies
Hematol 90:1077, 2015. for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol
15. Roufosse F, Garaud S, de Leval L: Lymphoproliferative disorders associ- 55:633, 2015.
ated with hypereosinophilia. Semin Hematol 49:138, 2012.